Loading...

Alexa Fluor® 700 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_Alx700_041106
C57BL/6 mouse splenocytes stained with CD8 (clone 53-6.7) Alexa Fluor® 700 (filled histogram) or rat IgG2a, κ Alexa Fluor® 700 isotype control (open histogram).
  • 53-6dot7_Alx700_041106
    C57BL/6 mouse splenocytes stained with CD8 (clone 53-6.7) Alexa Fluor® 700 (filled histogram) or rat IgG2a, κ Alexa Fluor® 700 isotype control (open histogram).
Compare all formats See Alexa Fluor® 700 spectral data
Cat # Size Price Quantity Check Availability Save
100729 25 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100730 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633nm / 635nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed
  2. Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed
  3. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  4. Roussel-Queval A, et al. 2023. STAR Protoc. 4:102119. PubMed
  5. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  6. Falahat R, et al. 2023. Nat Commun. 14:1573. PubMed
  7. Comeau K, et al. 2023. Bio Protoc. 13:e4679. PubMed
  8. Wang Y, et al. 2021. Cancer Res. 81:174. PubMed
  9. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  10. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  11. Abdelnabi MN, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:1269. PubMed
  12. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  13. Balood M, et al. 2022. Nature. 611:405. PubMed
  14. Edwards CL, et al. 2023. J Clin Invest. 133: . PubMed
  15. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  16. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  17. Cui B, et al. 2023. Int Immunopharmacol. 114:109541. PubMed
  18. Abu Hejleh AP, et al. 2023. Int J Tryptophan Res. 16:11786469231153111. PubMed
  19. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  20. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  21. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  22. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  23. Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed
  24. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  25. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  26. Herz J, et al. 2015. J Exp Med. 212: 1153 - 1169. PubMed
  27. Zhang YS, et al. 2018. Cancer Biol Ther. 19:735. PubMed
  28. Chen J, et al. 2021. Sci Adv. 7:. PubMed
  29. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  30. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  31. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  32. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  33. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  34. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  35. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  36. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  37. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  38. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  39. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  40. Ye M, et al. 2022. Nat Nanotechnol. 17:880. PubMed
  41. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  42. Liu X, et al. 2021. eLife. 0.416666666666667. PubMed
  43. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  44. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  45. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  46. Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed
  47. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  48. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  49. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  50. Ma C, et al. 2016. Nature. 531:253-257. PubMed
  51. Panciera T, et al. 2016. Cell Stem Cell. 19:725-737. PubMed
  52. Nakagawa P, et al. 2017. Physiol Rep. 10.14814/phy2.13084. PubMed
  53. Biancur DE, et al. 2020. Cell Metabolism. 33(1):199-210.e8. PubMed
  54. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  55. Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed
  56. Bunn P, et al. 2014. J Immunol. 192:3709. PubMed
  57. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  58. Wang F, et al. 2018. Carcinogenesis. 39:889. PubMed
  59. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  60. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  61. Pitsch J, et al. 2021. Ann Neurol. 89:666. PubMed
  62. Pérol L, et al. 2016. Nat Commun. 7:13027. PubMed
  63. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  64. Noah AC, et al. 2020. J Appl Physiol (1985). 473:128. PubMed
  65. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
  66. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  67. Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
  68. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  69. Yang Y, et al. 2021. Sci Adv. 7:eabf6290. PubMed
  70. Sobecki M, et al. 2021. Nat Commun. 12:4700. PubMed
  71. Carty S, et al. 2014. PLoS One. 9:106659. PubMed
  72. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  73. Qiao J, et al. 2019. Cancer Cell. 35:901. PubMed
  74. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  75. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  76. Zhu X et al. 2019. Cell reports. 27(4):1205-1220 . PubMed
  77. Solaymani-Mohammadi S, et al. 2016. J Leukoc Biol. 99: 475 - 482. PubMed
  78. Bronisz–Budzynska I, et al. 2019. Skelet Muscle. 9:22. PubMed
  79. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
  80. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  81. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  82. Penkert RR, et al. 2020. Obesity (Silver Spring). 1631:28. PubMed
  83. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  84. Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed
  85. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  86. Engel I, et al. 2016. Nat Immunol. 10.1038/ni.3437. PubMed
  87. Li C, et al. 2018. Cell. 174:285. PubMed
  88. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  89. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  90. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  91. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  92. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  93. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  94. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  95. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  96. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  97. Yan C, et al. 2022. NPJ Precis Oncol. 6:6. PubMed
  98. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  99. Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed
  100. McPhee C, et al. 2013. J Immunol. 191:4581. PubMed
  101. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  102. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  103. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  104. Fite BZ, et al. 2021. Sci Rep. 11:927. PubMed
  105. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  106. Rossnagl S, et al. 2016. PLoS Biol. 14: 1002562. PubMed
  107. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  108. Gawish R, et al. 2022. Elife. 11:. PubMed
  109. Hall JA, et al. 2020. Cell Metabolism. 32(4):665-675.e6. PubMed
  110. Engelbertsen D, et al. 2013. Arterioscler Thromb Vasc Biol. 33:637. PubMed
RRID
AB_493702 (BioLegend Cat. No. 100729)
AB_493702 (BioLegend Cat. No. 100730)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 06.27.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account